1. Balentine, DA, Wiseman, SA & Bouwens, LCM (1997) The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37, 693–704.
2. Hakim, IA, Alsaif, MA, Alduwaihy, M et al. (2003) Tea consumption and the prevalence of coronary heart disease in Saudi adults: results from a Saudi national study. Prev Med 36, 64–70.
3. Mukamal, KJ, Maclure, M, Muller, JE et al. (2002) Tea consumption and mortality after acute myocardial infarction. Circulation 105, 2476–2481.
4. Basu, A & Lucas, EA (2007) Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 65, 361–375.
5. Inami, S, Takano, M, Yamamoto, M et al. (2008) Tea catechin consumption reduces circulating oxidized low-density lipoprotein. Int Heart J 48, 725–732.
6. O’Keefe, JH, Gheewala, NM & O’Keefe, J (2008) Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 51, 249–255.
7. Tipoe, GL, Leung, TM, Hung, MW et al. (2007) Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection. Cardiovasc Hematol Disord Drug Targets 7, 135–144.
8. Kim, SK, Kim, HJ, Choi, SE et al. (2008) Anti-oxidative and inhibitory activities on nitric oxide (NO) and prostaglandin E2 (COX-2) production of flavonoids from seeds of Prunus tomentosa Thunberg. Arch Pharm Res 31, 424–428.
9. Ahmed, S, Rahman, A, Hasnain, A et al. (2002) Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 33, 1097–1105.
10. Miura, Y, Chiba, T, Tomita, L et al. (2001) Tea catechins prevent the development of atherosclerosis in apoprotein e-deficient mice. J Nutr 131, 27–32.
11. Persson, IA-L, Josefsson, M, Persson, K et al. (2006) Tea flavanols inhibit angiotensin-converting enzyme activity and increase nitric oxide production in human endothelial cells. J Pharm Pharmacol 58, 1139–1144.
12. Bramati, L, Aquiland, F & Pietta, P (2003) Unfermented Rooibos tea. Quantitative characterization of flavonoids by HPLC-UV and determination of the total antioxidant activity. J Agric Food Chem 51, 7472–7474.
13. Nishimura, H (2000) Angiotensin receptors – evolutionary overview and perspectives. Comp Biochem Physiol 128, 11–30.
14. Benson, SC, Iguchi, R, Ho, CI et al. (2008) Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens 26, 973–980.
15. Fogari, R & Zoppi, A (2006) Antihypertensive drugs and fibrinolytic function. Am J Hypertens 19, 1293–1299.
16. Rush, JW & Aultman, CD (2008) Vascular biology of angiotensin and the impact of physical activity. Appl Physiol Nutr Metab 33, 162–172.
17. Weiss, D, Sorescu, D & Taylor, WR (2001) Angiotensin II and atherosclerosis. Am J Cardiol 87, 25C–32C.
18. Birkenhäger, WH & Staessen, JA (2006) Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog Cardiovasc Dis 49, 1–10.
19. Gard, PR (2002) The role of angiotensin II in cognition and behavior. Eur J Pharmacol 438, 1–14.
20. McGuiness, B, Todd, S, Passmore, P et al. (2006) Blood pressure lowering in patients without prior cerebrovascular disease for comparative pharmacological interruption of the renin system. Hypertension 32, 387–392.
21. Reed, R, Kolz, C, Potter, B et al. (2008) The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth. Arterioscler Thromb Vasc Biol 28, 61–67.
22. Rigat, B, Hubert, C, Alhenc-Gelas, F et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86, 1343–1346.
23. Tiret, L, Rigat, B, Visvikis, S et al. (1992) Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51, 197–205.
24. Beohar, N, Damaraju, S, Prather, A et al. (1995) Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Investig Med 43, 275–280.
25. Cambien, F, Poirier, O, Lecerf, L et al. (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359, 641–644.
26. Samani, NJ, Thompson, JR, O’Toole, L et al. (1996) A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94, 708–712.
27. Millatt, LJ, Abdel-Rahman, EM & Siragy, HM (1999) Angiotensin II and nitric oxide: a question of balance. Regul Pept 81, 1–10.
28. Fernándes-Alfonso, MS & González, C (1999) Nitric oxide and the renin–angiotensin system. Is there a physiological interplay between the systems? J Hypertens 17, 1355–1361.
29. Kurz, S, Hink, U, Nickenig, G et al. (1999) Evidence for a causal role of the renin–angiotensin system in nitrate tolerance. Circulation 99, 3181–3187.
30. Ackermann, A, Fernández-Alfonso, MS, Sánchez de Rojas, R et al. (1998) Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol 124, 291–298.
31. Persson, K & Andersson, RGG (1999) Nitric oxide modulates captopril-mediated angiotensin-converting enzyme inhibition in porcine iliac arteries. Eur J Pharmacol 385, 21–27.
32. Persson, K, Whiss, PW, Nyhlén, K et al. (2000) Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro. Eur J Pharmacol 406, 15–23.
33. Lauer, T, Preik, M, Rassaf, T et al. (2001) Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA 98, 12814–12819.
34. Cheon, KT, Choi, KH, Lee, HB et al. (2000) Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 178, 351–360.
35. Karakaya, S (2004) Bioavailability of phenolic compounds. Crit Rev Food Sci Nutr 44, 453–464.
36. Cambien, F (1994) The angiotensin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infarction. Clin Genet 46, 94–101.
37. Persson, K, Säfholm, ACE, Andersson, RGG et al. (2005) Glyceryl trinitrate-induced angiotensin-converting enzyme (ACE) inhibition in healthy volunteers is dependent on ACE genotype. Can J Physiol Pharmacol 83, 1117–1122.
38. Danser, AHJ, Batenburg, WW, van den Meiracker, AH et al. (2007) ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibitors? Pharmacol Ther 113, 607–618.
39. Persson, IA-L, Lindén, E, Andersson, M et al. (2008) Effects of Ginkgo biloba extract EGb 761 and its terpene-lactones on angiotensin converting enzyme activity and nitric oxide production in human endothelial cells. Asian J Trad Med 3, 42–51.
40. Berecek, K & Zhang, L (1995) Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors. Adv Exp Med Biol 377, 141–168.
41. Abrams, WB, Davies, RO & Gomez, HJ (1984) Clinical pharmacology of enalapril. J Hypertens Suppl 2, 31–36.
42. Grassi, D, Mulder, TPJ, Draijer, R et al. (2009) Black tea consumption dose-dependently improves flow-mediated dilation in healthy males. J Hypertens 27, 774–781.
43. Hooper, L, Kroon, PA, Rimm, EB et al. (2008) Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 88, 38–50.
44. Allen, RR, Carson, L, Kwik-Uribe, C et al. (2008) Daily consumption of a dark chocolate containing flavanols and added sterol esters affect cardiovascular risk factors in a normotensive population with elevated cholesterol. J Nutr 138, 725–731.
45. Chen, CM, Zhao, W, Yang, Z et al. (2008) The role of dietary factors in chronic disease control in China. Obes Rev 9, Suppl. 1, 100–103.
46. López, EP, Rice, C, Weddle, DO et al. (2008) The relationship among cardiovascular risk factors, diet patterns, alcohol consumption, and ethnicity among women aged 50 years and older. J Am Diet Assoc 108, 248–256.
47. Patterson, C, Feightner, JW, Garcia, A et al. (2008) Diagnosis and treatment of dementia: risk assessment and primary prevention of Alzheimer disease. CMAJ 178, 548–556.
48. Dragsted, LO (2003) Antioxidant actions of polyphenols in humans. Int J Vitam Nutr Res 73, 112–119.
49. Aron, PM & Kennedy, JA (2008) Flavan-3-ols: nature, occurrence and biological activity. Mol Nutr Food Res 52, 79–104.
50. Boots, AW, Haenen, GRMM & Bast, A (2008) Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585, 325–337.
51. Hwang, J, Wang, J, Morazzoni, P et al. (2003) The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic Biol Med 34, 1271–1282.
52. Ikizler, M, Erkasap, N, Dernek, S et al. (2007) Dietary polyphenol quercetin protects rat hearts during reperfusion: enhanced antioxidant capacity with chronic treatment. Anatolian J Cardiol 7, 404–410.
53. Kaliora, AC & Dedoussis, GVZ (2007) Natural antioxidant compounds in risk factors for CVD. Pharmacol Res 56, 99–109.
54. Svarcova, I, Heinrich, J & Valentova, K (2007) Berry fruits as a source of biologically active compounds: the case of Lonicera caerulea. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151, 163–174.